|Articles|April 1, 1999

A Multidisciplined Approach to Improving the Treatment of Allergic Rhinitis in the Managed Care Popu
Volume 5
Issue 4 Suppl

Effect of Fexofenadine HC1 on Quality of Life and Work, Classroom, and Daily Activity Impairment in Patients with Seasonal Allergic Rhinitis

Author(s)L. Ann Tanner, RPh, MPH, Margaret Reilly, MA, MPH, Eli O. Meltzer, MD

Download PDF: Effect of Fexofenadine HC1 on Quality of Life and Work, Classroom, and Daily Activity Impairment in Patients with Seasonal Allergic Rhinitis

Articles in this issue

over 27 years ago

Article

Participating Faculty

over 27 years ago

Article

Selected Abstracts

over 27 years ago

Article

Bibliography

over 27 years ago

Article

The Role of the ECHO Model in Outcomes Research and Clinical Practice Improvement

over 27 years ago

Article

Economic Outcomes of a Targeted Intervention Program: The Costs of Treating Allergic Rhinitis Patients

over 27 years ago

Article

Diagnosis and Treatment of Allergic Rhinitis: Primary Care in an Integrated Health System Setting

over 27 years ago

Article

CME Quiz

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Subscribe

Related Content

Roles and Priorities Guiding Medicare Advantage Postacute Home Health Referrals

ByEmily A. Gadbois, PhD,Jennifer Bunker, MPH,Marguerite Daus, PhD, RN,Jamie M. Smith, PhD, RN,Emily Buss, MSN, RN,Christine D. Jones, MD, MS,Kali S. Thomas, PhD, MA

July 16th 2026

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

ByHeather L. Taylor, MPH, LDH,Ann M. Holmes, PhD,Nir Menachemi, PhD, MPH,Justin Blackburn, PhD

July 10th 2026

Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies

ByChristopher Scannell, MD, PhD,John A. Romley, PhD,Rebecca Myerson, PhD,Dana Goldman, PhD,Dima Mazen Qato, PharmD, PhD, MPH

July 9th 2026

Upper Payment Limit Implementation Risks for Patients, Pharmacies, and Providers

ByJulie A. Patterson, PharmD, PhD,Roswell A. Cole, PharmD, MPH,Jonathan D. Campbell, PhD, MS,John Michael O’Brien, PharmD, MPH

July 9th 2026

The New Oncology Blueprint: Integrating Clinical Intelligence for Sustainable Value

ByVivian T. E. Tar, PharmD, MBA

July 8th 2026

Effect of Fexofenadine HC1 on Quality of Life and Work, Classroom, and Daily Activity Impairment in Patients with Seasonal Allergic Rhinitis

Articles in this issue

Related Content

Roles and Priorities Guiding Medicare Advantage Postacute Home Health Referrals

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies

Upper Payment Limit Implementation Risks for Patients, Pharmacies, and Providers

The New Oncology Blueprint: Integrating Clinical Intelligence for Sustainable Value

Trending on AJMC

FDA Approves Enlicitide, First Oral PCSK9 for High Cholesterol

Home-Based Heart Failure Care Shows Comparable Safety to Continued Inpatient Care

Remote Monitoring Captured Between-Visit Symptom Swings in Myasthenia Gravis

Why Clinicians May Consider Obinutuzamab Over Rituximab in Follicular Lymphoma

Cardiology Prices Vary Widely by Insurer and State